Chemerin rs17173608 and vaspin rs2236242 gene variants on the risk of end stage renal disease (ESRD) and correlation with plasma malondialdehyde (MDA) level

References

• Aghighi M, Heidary Rouchi A, Zamyadi M, et al. Dialysis in Iran. Iran J Kidney Dis. 2008;2:11–15.
   PubMedGoogle Scholar
• Bellomo R, Ronco C, Kellum JA, et al. Acute renal failure–definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Critical Care. 2004;8:R204.
   PubMed Web of Science ®Google Scholar
• Barsoum RS. Chronic kidney disease in the developing world. N Engl J Med. 2006;354:997.
   PubMed Web of Science ®Google Scholar
• Yun Z, Yu-Ping Y, Zong-Wu T, et al. Association of endothelial nitric oxide synthase gene polymorphisms with end-stage renal disease: a systematic review and meta-analysis. Renal Failure. 2014;36:987–993.
   PubMed Web of Science ®Google Scholar
• Xue C, Nie W, Tang D, et al. Apolipoprotein E gene variants on the risk of end stage renal disease. PLoS One. 2013;8:e83367.
   PubMedGoogle Scholar
• Müssig K, Staiger H, Machicao F, et al. RARRES2, encoding the novel adipokine chemerin, is a genetic determinant of disproportionate regional body fat distribution: a comparative magnetic resonance imaging study. Metabolism. 2009;58:519–524.
   PubMed Web of Science ®Google Scholar
• Bozaoglu K, Curran JE, Stocker CJ, et al. Chemerin, a novel adipokine in the regulation of angiogenesis. J Clin Endocrinol Metab. 2010;95:2476–2485.
   PubMed Web of Science ®Google Scholar
• Roh S-g, Song S-H, Choi K-C, et al. Chemerin-a new adipokine that modulates adipogenesis via its own receptor. Biochem Biophys Res Commun. 2007;362:1013–1018.
   PubMed Web of Science ®Google Scholar
• Fatima SS, Rehman R, Baig M, et al. New roles of the multidimensional adipokine: chemerin. Peptides. 2014;62:15–20.
   PubMed Web of Science ®Google Scholar
• Barnea G, Strapps W, Herrada G, et al. The genetic design of signaling cascades to record receptor activation. Proc Natl Acad Sci. 2008;105:64–69.
   PubMed Web of Science ®Google Scholar
• Wittamer V, Franssen J-D, Vulcano M, et al. Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J Exp Med. 2003;198:977–985.
   PubMed Web of Science ®Google Scholar
• Zabel BA, Allen SJ, Kulig P, et al. Chemerin activation by serine proteases of the coagulation, fibrinolytic, and inflammatory cascades. J Biol Chem. 2005;280:34661–34666.
   PubMed Web of Science ®Google Scholar
• Parolini S, Santoro A, Marcenaro E, et al. The role of chemerin in the colocalization of NK and dendritic cell subsets into inflamed tissues. Blood. 2007;109:3625–3632.
   PubMed Web of Science ®Google Scholar
• Ernst MC, Sinal CJ. Chemerin: at the crossroads of inflammation and obesity. Trends Endocrinol Metab. 2010;21:660–667.
   PubMed Web of Science ®Google Scholar
• Rourke J, Dranse H, Sinal C. Towards an integrative approach to understanding the role of chemerin in human health and disease. Obes Rev. 2013;14:245–262.
   PubMed Web of Science ®Google Scholar
• Blaszak J, Szolkiewicz M, Sucajtys-Szulc E, et al. High serum chemerin level in CKD patients is related to kidney function, but not to its adipose tissue overproduction. Renal Failure. 2015;37:1033–1038.
   PubMed Web of Science ®Google Scholar
• Ernst MC, Issa M, Goralski KB, et al. Chemerin exacerbates glucose intolerance in mouse models of obesity and diabetes. Endocrinology. 2010;151:1998–2007.
   PubMed Web of Science ®Google Scholar
• Jha V, Garcia-Garcia G, Iseki K, et al. Chronic kidney disease: global dimension and perspectives. Lancet. 2013;382:260–272.
   PubMed Web of Science ®Google Scholar
• Leiherer A, Muendlein A, Kinz E, et al. High plasma chemerin is associated with renal dysfunction and predictive for cardiovascular events – insights from phenotype and genotype characterization. Vascul Pharmacol. 2016;77:60–68.
   PubMed Web of Science ®Google Scholar
• Kempf K, Rose B, Illig T, et al. Vaspin (SERPINA12) genotypes and risk of type 2 diabetes: results from the MONICA/KORA studies. Exp Clin Endocrinol Diabetes. 2010;118:184–189.
   PubMed Web of Science ®Google Scholar
• Heiker JT. Vaspin (serpinA12) in obesity, insulin resistance, and inflammation. J Pept Sci. 2014;20:299–306.
   PubMed Web of Science ®Google Scholar
• Yan M, Su B, Peng W, et al. Association of serum vaspin and adiponectin levels with renal function in patients with or without type 2 diabetes mellitus. J Diabetes Res. 2014;2014:868732.
   PubMedGoogle Scholar
• Nomani HH-NL, Aidy A, Vaisi-Raygani A, et al. Association between GSTM1, GSTT1, and GSTP1 variants and the risk of end stage renal disease. Ren Fail. 2016;38:1455–1461.
   PubMed Web of Science ®Google Scholar
• Locatelli F, Canaud B, Eckardt KU, et al. Oxidative stress in end‐stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant. 2003;18:1272–1280.
   PubMed Web of Science ®Google Scholar
• Nelson GJ, Morris VC, Schmidt PC, et al. The urinary excretion of thiobarbituric acid reactive substances and malondialdehyde by normal adult males after consuming a diet containing salmon. Lipids. 1993;28:757–761.
   PubMed Web of Science ®Google Scholar
• Bahrehmand FV-RA, Kiani A, Rahimi Z, et al. Matrix metalloproteinase-2 functional promoter polymorphism G1575A is associated with elevated circulatory MMP-2 levels and increased risk of cardiovascular disease in systemic lupus erythematosus patients. Lupus. 2012;21:616–624.
   PubMed Web of Science ®Google Scholar
• Boaz M, Matas Z, Biro A, et al. Serum malondialdehyde and prevalent cardiovascular disease in hemodialysis. Kidney Int. 1999;56:1078–1083.
   PubMed Web of Science ®Google Scholar
• Tanhapour M, Vaisi-Raygani A, Bahrehmand F, et al. Association between the cytotoxic T-lymphocyte antigen-4 mutations and the susceptibility to systemic lupus erythematosus; Contribution markers of inflammation and oxidative stress. Cell Mol Biol (Noisy-Le-Grand) 2016;62:56–61.
   PubMed Web of Science ®Google Scholar
• Tanhapour M, Miri A, Vaisi-Raygani A, et al. Synergism between apolipoprotein E ε4 allele and paraoxonase (PON1) 55-M allele is associated with risk of systemic lupus erythematosus. Clin Rheumatol. 2018;37:971–977.
   PubMed Web of Science ®Google Scholar
• Najafi K, Ahmadi S, Rahpeyma M, et al. Study of serum malondialdehyde level in opioid and methamphetamine dependent patients. Acta Med Iran. 2017;55:616–620.
   PubMedGoogle Scholar
• Bahrehmand F, Vaisi-Raygani A, Kiani A, et al. Matrix metalloproteinase 9 polymorphisms and systemic lupus erythematosus: correlation with systemic inflammatory markers and oxidative stress. Lupus. 2015;24:597–605.
   PubMed Web of Science ®Google Scholar
• Asefi M, Vaisi‐Raygani A, Khodarahmi R, et al. Methylentetrahydrofolatereductase (rs1801133) polymorphism and psoriasis: contribution to oxidative stress, lipid peroxidation and correlation with vascular adhesion protein 1, preliminary report. J Eur Acad Dermatol Venereol. 2014;28:1192–1198.
   PubMed Web of Science ®Google Scholar
• Agarwal R, Chase SD. Rapid, fluorimetric-liquid chromatographic determination of malondialdehyde in biological samples. J Chromatogr B Analyt Technol Biomed Life Sci. 2002;775:121–126.
   PubMed Web of Science ®Google Scholar
• Mohammadi Y, Vaisi-Raygani A, Shakiba E, et al. Angiotensin II type 1 receptor A1166 C (rs5186) gene polymorphism increased risk and severity of psoriasis, contribution to oxidative stress, antioxidant statues, lipid peroxidation and correlation with vascular adhesion protein 1, preliminary report. J Eur Acad Dermatol Venereol. 2016;30:1395–1397.
   PubMed Web of Science ®Google Scholar
• Hashemi M, Moazeni-roodi A, Bahari A, et al. A tetra-primer amplification refractory mutation system–polymerase chain reaction for the detection of rs8099917 IL28B genotype. Nucleosides, Nucleotides Nucleic Acids. 2012;31:55–60.
   PubMed Web of Science ®Google Scholar
• Etlik O, Koksal V, Arican-Baris ST, et al. Development and validation of a cost-effective in-house method, tetra-primer ARMS PCR assay, in genotyping of seven clinically important point mutations. Mol Cell Probes. 2011;25:177–181.
   PubMed Web of Science ®Google Scholar
• Hashemi M, Rezaei H, Eskandari-Nasab E, et al. Association between chemerin rs17173608 and vaspin rs2236242 gene polymorphisms and the metabolic syndrome, a preliminary report. Gene. 2012;510:113–117.
   PubMed Web of Science ®Google Scholar
• Asefi M, Vaisi‐Raygani A, Bahrehmand F, et al. Paraoxonase 1 (PON1) 55 polymorphism, lipid profiles and psoriasis. Br J Dermatol. 2012;167:1279–1286.
   PubMed Web of Science ®Google Scholar
• Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–612.
   PubMed Web of Science ®Google Scholar
• Chen H-Y, Lin C-C, Chiu Y-L, et al. Serum fetuin A and chemerin levels correlate with hepatic steatosis and regional adiposity in maintenance hemodialysis patients. PLoS One. 2012;7:e38415.
   PubMed Web of Science ®Google Scholar
• Pfau D, Bachmann A, Lössner U, et al. Serum levels of the adipokine chemerin in relation to renal function. Diabetes Care. 2010;33:171–173.
   PubMed Web of Science ®Google Scholar
• Rutkowski P, Sledzinski T, Zielinska H, et al. Decrease of serum chemerin concentration in patients with end stage renal disease after successful kidney transplantation. Regul Pept. 2012;173:55–59.
   PubMed Web of Science ®Google Scholar
• Freedman BI, Bowden DW. The role of genetic factors in the development of end-stage renal disease. Curr Opin Nephrol Hypertens. 1995;4:230–234.
   PubMedGoogle Scholar
• Imamura Y, Murayama N, Okudaira N, et al. Prediction of fluoroquinolone-induced elevation in serum creatinine levels: a case of drug-endogenous substance interaction involving the inhibition of renal secretion. Clin Pharmacol Ther. 2011;89:81–88.
   PubMed Web of Science ®Google Scholar
• Seeger J, Ziegelmeier M, Bachmann A, et al. Serum levels of the adipokine vaspin in relation to metabolic and renal parameters. J Clin Endocrinol Metab. 2008;93:247–251.
   PubMed Web of Science ®Google Scholar
• Hida K, Wada J, Eguchi J, et al. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci USA. 2005;102:10610–10615.
   PubMed Web of Science ®Google Scholar
• Handisurya A, Riedl M, Vila G, et al. Serum vaspin concentrations in relation to insulin sensitivity following RYGB-induced weight loss. Obes Surg. 2010;20:198–203.
   PubMed Web of Science ®Google Scholar
• Feng R, Li Y, Wang C, et al. Higher vaspin levels in subjects with obesity and type 2 diabetes mellitus: a meta-analysis. Diabetes Res Clin Pract. 2014;106:88–94.
   PubMed Web of Science ®Google Scholar
• Fülöp P, Seres I, Lőrincz H, et al. Association of chemerin with oxidative stress, inflammation and classical adipokines in non‐diabetic obese patients. J Cell Mol Med. 2014;18:1313–1320.
   PubMed Web of Science ®Google Scholar
• Yu S, Zhang Y, Li M, et al. Chemerin and apelin are positively correlated with inflammation in obese type 2 diabetic patients. Chin Med J. 2012;125:3440–3444.
   PubMed Web of Science ®Google Scholar